CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Rhea-AI Summary
CalciMedica Inc. (Nasdaq: CALC), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's CEO, Rachel Leheny, Ph.D., will deliver a presentation on September 9, 2024, at 7:00 a.m. ET/ 4:00 a.m. PT.
CalciMedica specializes in developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. Investors and interested parties can access a live webcast of the presentation through the company's IR website. The webcast replay will be available for 90 days following the event.
Positive
- None.
Negative
- None.
A live webcast of the presentation can be accessed in the "Upcoming Events" section of CalciMedica's IR website at https://ir.calcimedica.com/. A replay of the webcast will be archived on the Company's website for 90 days.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced topline data for a Phase 2b trial (called CARPO – NCT04681066) in patients with AP with SIRS and completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with AKI with associated AHRF with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in patients with AIPT with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-present-at-the-hc-wainwright-26th-annual-global-investment-conference-302234592.html
SOURCE CalciMedica, Inc.
FAQ
When is CalciMedica (CALC) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for CalciMedica (CALC) at the investment conference?
How can investors access CalciMedica's (CALC) presentation at the conference?
What is the focus of CalciMedica's (CALC) research and development?
How long will the replay of CalciMedica's (CALC) presentation be available?
